| Clinical experience with insulin glargine in type 1 diabetes. | |
| | |
MedLine Citation:
|
PMID: 20969435 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Diabetes Control and Complications Trial (DCCT) demonstrated the importance of optimal glycemic control achieved through intensive insulin therapy in reducing the microvascular complications associated with type 1 diabetes. However, the DCCT, which was conducted prior to the availability of insulin analogs, also reported a significant increase in severe hypoglycemia with intensive versus conventional therapy. Insulin analogs were developed to aid patients in achieving better diabetes control by providing insulins with optimized pharmacokinetic and pharmacodynamic characteristics. Insulin glargine was the first long-acting insulin analog with a 24-h duration of action, offering once-daily injection, and has now been in clinical use for over 10 years. The authors performed a systematic search of EMBASE, MEDLINE, and Web of Science (Science Citation Index) to determine the efficacy of insulin glargine in type 1 diabetes in basal-bolus insulin regimens. Randomized controlled trials have demonstrated that glycemic control with insulin glargine is at least comparable to that with neutral protamine Hagedorn (NPH) insulin in adults and in children and adolescents, and with continuous subcutaneous insulin infusion in adults. However, these same trials show a significantly lower risk for hypoglycemia with insulin glargine compared with NPH insulin in adults. |
| | |
Authors:
|
Satish Garg; Emily Moser; Marie-Paule Dain; Anastasia Rodionova |
Related Documents
:
|
16979255 - Evaluation of the superiority of insulin glargine as basal insulin replacement by conti... 2182505 - Unawareness of hypoglycemia by insulin-dependent diabetics. 19504715 - Intensification to biphasic insulin aspart 30/70 (biasp 30, novomix 30) can improve gly... 1739395 - Endocrine emergencies. hypoglycaemia. 19564455 - Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. 2272625 - Tracer studies of in vivo insulin action and glucose metabolism in individual periphera... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review Date: 2010-10-22 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: 12 ISSN: 1557-8593 ISO Abbreviation: Diabetes Technol. Ther. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2011-03-03 Revised Date: 2011-08-25 |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 835-46 Citation Subset: IM |
Affiliation:
|
Barbara Davis Campus for Childhood Diabetes, University of Colorado-Denver, 1775 Aurora Court, Aurora, CO 80045, USA. satish.garg@ucdenver.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Child Diabetes Mellitus, Type 1 / drug therapy* Drug Combinations Humans Hypoglycemic Agents / administration & dosage, adverse effects, therapeutic use* Infusions, Subcutaneous Injections, Subcutaneous Insulin / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use Insulin, Long-Acting / therapeutic use Patient Satisfaction Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/Hypoglycemic Agents; 0/Insulin, Long-Acting; 0/glargine; 11061-68-0/Insulin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A long way to tipperary? Young people with complex health conditions living in residential aged care...
Next Document: Treatment of burning mouth syndrome with a low-level energy diode laser.